Nxera Pharma Swings to Nine-Month Net Profit of JPY 2.33 Billion
Bitget2026/10/30 06:41- Nxera Pharma swung to a net profit of JPY 2.33 billion for the nine months ended September 30, 2026.
- Revenue rose 27% year-over-year to JPY 27.74 billion, while milestone revenue more than doubled to JPY 9.5 billion.
- In October, it licensed Fabry disease candidate lucerastat from Idorsia, with regulatory filings targeted as early as 2029.
- The full-year 2026 revenue forecast remains unchanged at JPY 33.8 billion to JPY 48.8 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price
Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
Crypto prices
More
